Inside Eli Lilly's Surging Stock Price

For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.
Publish date:

Eli Lilly (LLY) - Get Report expects revenue for 2017 to fall somewhere between $21.8 billion and $22.3 billion, as compared with consensus estimates of roughly $21.7 billion.

The company's shares bounced after dropping 1.4% the day before. 

Lilly traditionally guides during the first week of January, but moved it up in light of results from its decision to change endpoints for its Alzheimer's drug, solanezumab.

The guidance follows Lilly's announcement on Tuesday that it has partnered with Express Scripts (ESRX)  to lower the cost of insulin for patients who were paying the most.

This article was written by a staff member of TheStreet.